

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform its shareholders and potential investors that despite the adverse impacts such as the recurrence of the COVID-19 pandemic for the year ended 31 December 2022, the Group still made remarkable progress in the marketing and commercialization of its flagship products, and is expected that the revenue of the Company for the year ended 31 December 2022 would achieve a year-on-year growth of over 850% as compared to that for the year ended 31 December 2021 based on the preliminary review of the unaudited management accounts of the Group and the information available to the Company as at the date of this announcement.

For the purpose of pursuing on establishing a surgical robot technology innovation platform and industrial operation system, during the year ended 31 December 2022, the Group continued to maintain intensive inputs in the research and development, clinical registration, and commercialization activities. Thus, despite the expected growth of revenue for the year ended 31 December 2022, the Company is expected to keep a loss-making trend for the year ended 31 December 2022 (the net loss is expected in the range of approximately RMB1,100 million to approximately RMB1,150 million).

As at the date of this announcement, the Company is still in the process of preparing and completing the annual results of the Company for the year ended 31 December 2022. The information contained in this announcement is only based on a preliminary assessment of the consolidated management accounts and relevant information available to the Board as of the date of the announcement, which has not been

audited or reviewed by the Company's auditors or reviewed by the audit committee of the Board, and may be subject to adjustments. The audited annual results announcement of the Company for the year ended 31 December 2022 will be published on or before 31 March 2023. Shareholders of the Company and potential investors are advised to read carefully the audited annual results announcement upon publication.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 1 March 2023

As at the date of this announcement, the executive Director is Dr. He Chao, the non-executive Directors are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.